Cargando…

Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study

Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbelli, Ilenia, Verzina, Angela, Leone De Magistris, Ilaria, De Vanna, Gioacchino, Eusebi, Paolo, Mataluni, Giorgia, Pisani, Antonio, Prudenzano, Addolorata Maria Pia, Trojano, Maria, Delussi, Marianna, De Tommaso, Marina, Russo, Antonio, Silvestro, Marcello, Tedeschi, Gioacchino, Calabresi, Paolo, Sarchielli, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863104/
https://www.ncbi.nlm.nih.gov/pubmed/36668854
http://dx.doi.org/10.3390/toxins15010034
_version_ 1784875253176991744
author Corbelli, Ilenia
Verzina, Angela
Leone De Magistris, Ilaria
De Vanna, Gioacchino
Eusebi, Paolo
Mataluni, Giorgia
Pisani, Antonio
Prudenzano, Addolorata Maria Pia
Trojano, Maria
Delussi, Marianna
De Tommaso, Marina
Russo, Antonio
Silvestro, Marcello
Tedeschi, Gioacchino
Calabresi, Paolo
Sarchielli, Paola
author_facet Corbelli, Ilenia
Verzina, Angela
Leone De Magistris, Ilaria
De Vanna, Gioacchino
Eusebi, Paolo
Mataluni, Giorgia
Pisani, Antonio
Prudenzano, Addolorata Maria Pia
Trojano, Maria
Delussi, Marianna
De Tommaso, Marina
Russo, Antonio
Silvestro, Marcello
Tedeschi, Gioacchino
Calabresi, Paolo
Sarchielli, Paola
author_sort Corbelli, Ilenia
collection PubMed
description Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, every 3 months for 5 cycles (Phase 1). In the Phase 2 of the study, depending on response rate, patients were divided into “responders” (R), “partially responders” (PR) and “non-responders” (NR). Then, we proposed to R and PR patients to continue with an additional 12 months of treatment (additional 4 sessions). Response to treatment and adverse events were collected for the entire duration of the study. Of the 195 patients included (females 82.1%, mean age 47.4 ± 12.4), at the end of Phase 1 there were 52.3% of R patients, 17.9% of PR patients, 15.4% of NR patients and 14.4% drop-outs. During Phase 2 of treatment, R patients presented a maintenance of the improvement achieved during the first year of treatment, as well as PR patients. Except for three serious adverse events not related to treatment, all other adverse events were mild or moderate in severity and resolved without sequelae. In the literature, adherence to oral migraine-preventive medications among patients with CM was found to be less than 25%. The results of this prospective real-life multicenter study show efficacy, safety and adherence to a long-term treatment with onaBT-A.
format Online
Article
Text
id pubmed-9863104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98631042023-01-22 Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study Corbelli, Ilenia Verzina, Angela Leone De Magistris, Ilaria De Vanna, Gioacchino Eusebi, Paolo Mataluni, Giorgia Pisani, Antonio Prudenzano, Addolorata Maria Pia Trojano, Maria Delussi, Marianna De Tommaso, Marina Russo, Antonio Silvestro, Marcello Tedeschi, Gioacchino Calabresi, Paolo Sarchielli, Paola Toxins (Basel) Article Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, every 3 months for 5 cycles (Phase 1). In the Phase 2 of the study, depending on response rate, patients were divided into “responders” (R), “partially responders” (PR) and “non-responders” (NR). Then, we proposed to R and PR patients to continue with an additional 12 months of treatment (additional 4 sessions). Response to treatment and adverse events were collected for the entire duration of the study. Of the 195 patients included (females 82.1%, mean age 47.4 ± 12.4), at the end of Phase 1 there were 52.3% of R patients, 17.9% of PR patients, 15.4% of NR patients and 14.4% drop-outs. During Phase 2 of treatment, R patients presented a maintenance of the improvement achieved during the first year of treatment, as well as PR patients. Except for three serious adverse events not related to treatment, all other adverse events were mild or moderate in severity and resolved without sequelae. In the literature, adherence to oral migraine-preventive medications among patients with CM was found to be less than 25%. The results of this prospective real-life multicenter study show efficacy, safety and adherence to a long-term treatment with onaBT-A. MDPI 2022-12-31 /pmc/articles/PMC9863104/ /pubmed/36668854 http://dx.doi.org/10.3390/toxins15010034 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Corbelli, Ilenia
Verzina, Angela
Leone De Magistris, Ilaria
De Vanna, Gioacchino
Eusebi, Paolo
Mataluni, Giorgia
Pisani, Antonio
Prudenzano, Addolorata Maria Pia
Trojano, Maria
Delussi, Marianna
De Tommaso, Marina
Russo, Antonio
Silvestro, Marcello
Tedeschi, Gioacchino
Calabresi, Paolo
Sarchielli, Paola
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title_full Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title_fullStr Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title_full_unstemmed Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title_short Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
title_sort sustained efficacy, safety and high adherence rate of onabotulinum toxin type a in chronic migraine patients: a multicentric prospective real-life study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863104/
https://www.ncbi.nlm.nih.gov/pubmed/36668854
http://dx.doi.org/10.3390/toxins15010034
work_keys_str_mv AT corbelliilenia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT verzinaangela sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT leonedemagistrisilaria sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT devannagioacchino sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT eusebipaolo sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT matalunigiorgia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT pisaniantonio sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT prudenzanoaddoloratamariapia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT trojanomaria sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT delussimarianna sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT detommasomarina sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT russoantonio sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT silvestromarcello sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT tedeschigioacchino sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT calabresipaolo sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy
AT sarchiellipaola sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy